<DOC>
	<DOCNO>NCT00974155</DOCNO>
	<brief_summary>The EMC trial investigates first time prospectively whether Major Depression Disorder patient non-improvement 14 day antidepressive treatment EMC likely become remitters compare patient treat accord current guideline , i.e. , medication change 28 day treatment case non-response .</brief_summary>
	<brief_title>The Early Medication Change ( EMC ) Trial</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Major Depressive Disorder ( MDD ) , first episode recurrent , accord DSM‐IV HAMD17 score ≥18 pt . Age 18 65 year age ≤ 60 year time first depressive episode Ability subject understand character individual consequence clinical trial Signed date informed consent subject must available start specific trial procedure . Acute risk suicide need intervention comprise protocol treatment ( e.g . electroconvulsive therapy ) Patients lifetime DSM‐IV diagnosis dementia , schizophrenia , schizoaffective disorder , bipolar disorder Patients current DSM‐IV diagnosis posttraumatic stress disorder , obsessive‐compulsive disorder , anxiety disorder , eat disorder requirement treatment comprise protocol treatment Patients DSM‐IV substance dependency require acute detoxification Depression due organic brain disorder , e.g . Multiple Sclerosis Parkinson 's Disease Women pregnant , breastfeed plan become pregnant trial Women sterile surgery two year postmenopausal woman childbearing potential practicing medically accept contraception trial Patients currently take antidepressant medication , start within 2‐4 week prior study begin continuation antidepressant medication clinically indicate A clear history non‐response adequate treatment trial current major depressive episode protocol antidepressant . A `` clear history non‐response '' assume , follow criterion fulfil : ad Escitalopram : Treatment mDDD ≥ 15 mg/d 4 week CPL 15‐80 ng/ml four week without response , i.e . symptom reduction ≥ 50 % start end treatment . ad Venlafaxine : Treatment mDDD ≥ 300 mg/d 4 week CPL 195‐400 ng/ml four week without response , i.e . symptom reduction ≥ 50 % start end treatment ; ad Lithium : Treatment CPL 0.6‐0.8 mmol Li+ four week without response , i.e . symptom reduction ≥ 50 % start end treatment History medical psychological condition , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug render patient high risk treatment complication History hypersensitivity investigational medicinal product drug similar chemical structure excipient present pharmaceutical form investigational medicinal product Clinically significant unstable medical surgical condition may preclude safe complete study participation . Such condition may include gastrointestinal , cardiovascular , vascular disease , pulmonary/respiratory , hepatic impairment , renal , metabolic disease , endocrinological , neurological , immune‐deficiency , hematopoietic disease , malignancy determine medical history , physical examination , laboratory test Participation clinical trial present clinical trial within last 6 month Medical psychological condition would permit sign informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Major</keyword>
	<keyword>Depression</keyword>
	<keyword>Disorder</keyword>
</DOC>